Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.
Research Interests

Papers共 65 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study
Sandra Rajme-López,Bernardo A. Martinez-Guerra,Carla M. Román-Montes,Karla M. Tamez-Torres, Andrea C. Tello-Mercado, Karen M. Tepo-Ponce, Zurisadai Segura-Ortíz, Abigail López-Aguirre, Orianlid del Rocío Gutiérrez-Mazariegos, Oswaldo Lazcano-Delgadillo,Rafael Nares-López,María F. González-Lara,
Therapeutic Advances in Infectious Disease (2024)
Cited0Views0Bibtex
0
0
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study
Sandra Rajme-López,Bernardo A Martinez-Guerra,Carla M Román-Montes,Karla M Tamez-Torres, Andrea C Tello-Mercado, Karen M Tepo-Ponce, Zurisadai Segura-Ortíz, Abigail López-Aguirre, Orianlid Del Rocío Gutiérrez-Mazariegos, Oswaldo Lazcano-Delgadillo,Rafael Nares-López,María F González-Lara,
Therapeutic advances in infectious disease (2024): 20499361241236582-20499361241236582
Cited0Views0WOSBibtex
0
0
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study
Sandra Rajme-López,Bernardo A. Martinez-Guerra,Carla M. Román-Montes,Karla M. Tamez-Torres, Andrea C. Tello-Mercado, Karen M. Tepo-Ponce, Zurisadai Segura-Ortíz, Abigail López-Aguirre, Orianlid del Rocío Gutiérrez-Mazariegos, Oswaldo Lazcano-Delgadillo,Rafael Nares-López,María F. González-Lara,
Therapeutic Advances in Infectious Disease (2024)
Cited0Views0Bibtex
0
0
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study
Sandra Rajme-Lopez,Bernardo A. Martinez-Guerra,Carla M. Roman-Montes,Karla M. Tamez-Torres, Andrea C. Tello-Mercado, Karen M. Tepo-Ponce, Zurisadai Segura-Ortiz, Abigail Lopez-Aguirre, Orianlid del Rocio Gutierrez-Mazariegos, Oswaldo Lazcano-Delgadillo,Rafael Nares-Lopez,Maria F. Gonzalez-Lara,
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE (2024)
Cited0Views0Bibtex
0
0
Outbreak of Fusarium solani Meningitis in Immunocompetent Persons Associated With Neuraxial Blockade in Durango, Mexico, 2022-2023
Gabriel Garcia-Rodriguez,Celida Duque-Molina, Irasema Kondo-Padilla, Christian Arturo Zaragoza-Jimenez, Vladimir Brian Gonzalez-Cortes, Rocio Flores-Antonio,Tania Villa-Reyes, Adriana Vargas-Rubalcava, Luis Angel Ruano-Calderon, Juan Carlos Tinoco-Favila, Hector Carlos Sanchez-Salazar, Rodolfo Rivas-Ruiz,
OPEN FORUM INFECTIOUS DISEASES（2024）
Cited0Views0WOSBibtex
0
0
Risk Factors Associated with the Development of Hospital-Acquired Infections in Hospitalized Patients with Severe COVID-19
Fernando Solis-Huerta,Bernardo Alfonso Martinez-Guerra,Carla Marina Roman-Montes,Karla Maria Tamez-Torres,Sandra Rajme-Lopez, Narciso Ortiz-Conchi, Norma Irene Lopez-Garcia, Guadalupe Yvonne Villalobos-Zapata,Andrea Rangel-Cordero,Janet Santiago-Cruz, Luis Fernando Xancal-Salvador,Steven Mendez-Ramos,
ANTIBIOTICS-BASELno. 7 (2023): 1108-1108
Cited0Views0WOSBibtex
0
0
Load More
Author Statistics
  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn